New Hope For Basal Cell Carcinoma

New Hope For Basal Cell Carcinoma

The Science Behind The Latest FDA Approval Strong Phase II data launched Novartis’ (Basel, Switzerland) Odomzo to an accelerated FDA approval for basal cell carcinoma last week. The company skipped Phase III testing for the skin cancer drug because 58% of...